OncoMatch

OncoMatch/Clinical Trials/NCT04107077

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

Is NCT04107077 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cisplatin and Mitomycin for gastric cancer.

Phase 2RecruitingUniversity of ChicagoNCT04107077Data as of May 2026

Treatment: Cisplatin · MitomycinTo assess if PD-L1 expression can be upregulated in peritoneal metastases from gastric cancer after the administration of HIPEC with greater frequency compared to systemic chemotherapy alone

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Ovarian Cancer

Disease stage

Metastatic disease required

GC/PM only and/or positive peritoneal cytology

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: systemic chemotherapy

completed prior systemic chemotherapy for a minimum of 2 to 4 months duration

Lab requirements

Blood counts

leukocytes ≥3,000/mcL; absolute neutrophil count ≥1,500/mcL; platelets ≥100,000/mcL

Kidney function

creatinine ≤ institutional ULN OR GFR ≥50 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2

Liver function

total bilirubin ≤ institutional upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN

Cardiac function

NYHA Functional Classification class 2B or better

adequate organ and marrow function as defined below: leukocytes ≥3,000/mcL; absolute neutrophil count ≥1,500/mcL; platelets ≥100,000/mcL; total bilirubin ≤ institutional upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN; creatinine ≤ institutional ULN OR GFR ≥50 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2. ... cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Chicago · Chicago, Illinois

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify